Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAGIC Phase 2 study of DNTH103 in adults with generalized myasthenia gravis
2024-512865-15-00Phase 2Authorised
- Sponsor
- Dianthus Therapeutics
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 15
01
Overview
Phase 2, randomised, double-blind trial in myasthenia gravis (MG) comparing DNTH103 with Placebo (2 arms). Primary endpoint: Safety and tolerability up to Week 13. Planned start Jul 2024; status: authorised.
02
Drugs
claseprubart
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2024-512865-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512865-15-00.